This is the first study to evaluate the effects of saroglitazar, a dual PPAR-α/γ agonist, on insulin sensitivity by hyperinsulinemic euglycemic clamp in patients of T2DM with hypertriglyceridemia. Here, PPARA is linked to type 2 diabetes mellitus.